We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 876

Life Sciences & Antitrust: Cases to Watch in 2018
  • Paul Hastings LLP
  • USA
  • January 17 2018

The intersection of complex drug competition frameworks and the antitrust laws continues to grow. With increased collaboration between the Food and


Amgen Moves to Dismiss Genentech’s Misrepresentation Claim
  • Morgan Lewis
  • USA
  • January 9 2018

Amgen paints a different picture as to the bad actor during the parties’ negotiations pursuant to the Biologics Price Competition and Innovation Act


Antitrust Remains in Political Crosshairs for 2018 Midterm Elections
  • McDermott Will & Emery
  • USA
  • December 14 2017

Senator Elizabeth Warren (D-MA) gave a speech at the Open Markets Institute on December 6 entitled “Three Ways to Remake the American


Life sciences: product regulation and liability in the USA
  • Perkins Coie LLP
  • USA, Global
  • October 11 2017

A structured guide to product regulation and liability in the USA


Third Circuit Holds No Sham Litigation or Unlawful Reverse Payment in Wellbutrin XL Litigation
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 25 2017

The Third Circuit recently affirmed the grant of summary judgment to GlaxoSmithKline (“GSK”) in the nearly 10-year-old Wellbutrin XL Antitrust


The Supreme Court’s Decision in Amgen v. Sandoz: Clear Guidance and Open Questions for Biosimilars
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 21 2017

As we previously reported here, earlier this year the Supreme Court agreed to hear its first case arising under the Biosimilars Price Competition and


Opportunity - FDA encouraging manufacture and distribution of new generic drugs
  • Innofy
  • USA
  • July 21 2017

The U.S. Food and Drug Administration (FDA) are desperately seeking to increase competition for prescription drugs. The reasons for this are of no


FDA Holds Public Meeting on Innovation in Drug Development and Accelerating Access to Generic Medicines
  • Arent Fox LLP
  • USA
  • July 20 2017

On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and Accelerating the access


FDA Increases Priority Review Opportunities for Drug Products with Limited Competition
  • Duane Morris LLP
  • USA
  • July 18 2017

The FDA hopes to increase market competition for prescription drugs and facilitate entry of lower-cost alternatives. Following the Drug Competition


FDA Stays in the Spotlight with Drug Pricing Moves, but Could Be Facing Risk as UFA Bill Loses Attention
  • Mintz Levin
  • USA
  • June 30 2017

It appears that - at least for now - the U.S. Food and Drug Administration (FDA) is serving as the public face of the executive branch's efforts to